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ABSTRACT
Prasugrel is a thienopyridine that was approved by the US Food and Drug
Administration in combination with aspirin for the reduction of thrombotic events
as well as stent thrombosis in patients with acute coronary syndrome who undergo
percutaneous coronary intervention. This retrospective study aims to assess the
frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs
more attention as inappropriate use may result in significant morbidity.
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BACKGROUND
The cornerstone in the management of acute
coronary syndrome (ACS) is dual antiplatelet therapy
(DAPT) including aspirin and P2Y12 inhibitors.1
DAPT is most beneficial for patients undergoing
percutaneous coronary intervention (PCI); it is known
to reduce the occurrence of stent thrombosis and
major cardiac events.2-4 Clopidogrel is the most
commonly used P2Y12 inhibitor. Limitations of
clopidogrel include variable antiplatelet effect5 and
delayed onset of action.3 This variability in the efficacy
of clopidogrel paved the way for newer P2Y12
inhibitors such as prasugrel to be used in selective
cases.
Prasugrel is a thienopyridine that was approved
by the US Food and Drug Administration (FDA)
in combination with aspirin for the reduction of
thrombotic events as well as stent thrombosis in
patients with ACS who undergo PCI. As prasugrel
is a prodrug, it requires conversion to an active
metabolite before binding to the P2Y12 receptor.6
TRITON-TIMI 38 was a randomized clinical trial which
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compared prasugrel and clopidogrel in patients with
ACS and concluded that prasugrel (in comparison
to clopidogrel) has an early onset of action and
provides significant inhibition of platelet aggregation
in patients with ACS,7,8 thereby significantly reducing
rate of stent thrombosis and ischemic events in
patient undergoing PCI. While there is an obvious
benefit over clopidogrel, prasugrel is also associated
with increased risk for major bleeding.8 This risk of
bleeding led to the conclusion that there is no net
benefit of prasugrel in patients with previous stroke
or transient ischemic attack (TIA), patients older
than 75 years, and patients weighing <60 kg; it was
concluded that it caused net harm.8-10 For these
reasons, use of prasugrel in such patient populations
is a class III recommendation.1
This retrospective study aims to assess the frequency
of inappropriate use of prasugrel and to emphasize
that prasugrel still needs more attention as
inappropriate use may result in significant morbidity.
Methods
Study design and patient population
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This is a single center retrospective study
to determine the inappropriate use of
prasugrel in patients during the period
between July 2014 and July 2015. Use
of prasugrel in patients with history of
cerebrovascular disease (CVA) or history
of bleed or in patients who weigh <60
kg, or patient with age of ≥75 years was
deemed as inappropriate. No exclusion
criteria were applied. Marshall University’s
institutional review board approved the
study.
Endpoints
The primary study endpoint was the number of
patients discharged to home on prasugrel. Secondary
endpoints included patients prescribed prasugrel
who had a history of CVA or bleed, weighed <60kg, or
were of age ≥75 years.
Data collection
Patient’s clinical characteristics, demographics, as
well as primary and secondary endpoints, were
retrospectively collected from the patient’s electronic
medical records.

CHART 1 Frequency of inappropriate use of Prasugrel

used for patients who did not receive stents during
their procedure; the incidence was calculated as
3.2% (n=4). Among patients who were prescribed
prasugrel, 16.9% (n=21) presented with ST-elevation
myocardial infarction, 24.2% (n=30) presented with
non-ST elevation myocardial infarction, while 45.2%
(n=56) patients had unstable angina and 13.7%
(n=17) patients received prasugrel after elective PCI
(Table 1).

Statistical analysis
Categorical variables were presented as
percentages.
RESULTS
Duration of this study was July 2014 to
July 2015. A total of 937 patients had
PCI during this time; prasugrel was
prescribed to 124 (12.3%). Prasugrel was
inappropriately used in 18.5% (n=23) of
patients. Of these patients, 4.8% (n=6) had
a history of CVA, 1.6% (n=2) had a history
of bleeding, 10.5% (n=13) were aged ≥75
years and 1.6% (n=2) weighed less than
60kg (Chart 1).

TABLE 1: Demographics of patients who received
prasugrel.

Our data demonstrated that prasugrel was also
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DISCUSSION
As stated in the 2016 update of the American
College of Cardiology/American Heart Association
DAPT guidelines prasugrel can only be used in place
of clopidogrel in patients with ACS if the patient
is not at an increased risk of bleeding; this is a
Class IIB recommendation.1 This recommendation
was based on the findings of the TRITON–TIMI 38
trial, which concluded that prasugrel significantly
decreases ischemic complications of ACS in patients
undergoing PCI in comparison to clopidogrel.11
The same study also found that prasugrel, when
used as a part of DAPT in a patient with a history of
cerebrovascular event, patients aged 75 or older,
and those weighing <60 kg, had increased rate of
fatal bleeding. The aim of our study was to report the
prevalence of inappropriate use of prasugrel.
Our study demonstrates that the inappropriate use
of prasugrel is significant and it affects a sizable
portion of the patients requiring antiplatelet
therapy. Secondly, we were able to deduce that
the inappropriate use of prasugrel most frequently
occurs when it is prescribed to patients aged >75
years; in our sample it was a staggering 10.5%.
Alexopoulos et al., reported that age ≥ 75 years is
a common inappropriate use of P2Y12 inhibitor
(not limited to prasugrel).12 It would be noteworthy
to mention that the rate of bleeding requiring
transfusion was found to be significantly higher
for patients receiving prasugrel inappropriately as
compared with those receiving the drug under no
contraindications.13
Alexopoulos et al. studied the Greek antiplatelet
registry (GRAPE) and reported that 10.6% of the
patients were inappropriately prescribed prasugrel
on discharge.12 In comparison to the GRAPE registry,
our data shows that 18.5% patients were prescribed
prasugrel inappropriately. Hira et al. studied
PINNACLE national registry and found that 13.9%
patients were inappropriately prescribed prasugrel
while 4.4% patients were prescribed prasugrel for
non-recommended indications;14 the cumulative use
was 18.3% which is consistent with findings of our
study.
Variability in the prevalence of inappropriate
use of prasugrel in the above-mentioned studies
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can be attributed to the difference in definition
of “inappropriate use.” Randomized studies that
established the value of the P2Y12 inhibitors
in the treatment of ACS patients undergoing
PCI had excluded patients with many of the
contraindications and special warnings mainly
because of the accompanying increased risk of
bleeding, without reporting on the prevalence of
these characteristics in screened patients.15 Such
clinical research practice led to masking of valuable
information about the population that is possibly
affected the most by inappropriate use of prasugrel.
Secondly, the definition of our study does not
differentiate between non-recommended use or
inappropriate use. Hence, our data reports a higher
rate of inappropriate use.
Prasugrel was also used in patients who had an
elective PCI, the proportion of such patients was
13.7% of our data. Use of prasugrel in this capacity
has not been studied in detail.16 Marchini et al.
devised an algorithm for prasugrel use in 2010
but concluded that the use of prasugrel might
be considered for patients where the coronary
artery anatomy is “high-risk” and patients who
have homozygous reduced-function CYP allele
which renders clopidogrel hypo-responsive.16 In
2012, TRIGGER-PCI study by Trenk et al. compared
prasugrel and clopidogrel after elective PCI,
and found that P2Y12 reaction unit (PRU) was
significantly reduced in the prasugrel arm of the
study. The study, however, could not demonstrate
the benefit of prescribing prasugrel over clopidogrel
in terms of endpoints which included cardiac death
and myocardial infarction in six months.17
Damman et al. in 2014 reported that in respect to
elective PCI, occurrence of mortality and bleeding
was comparable between the clopidogrel group
and the prasugrel group.18 A recent randomized
clinical trial by Hochholzer et al. “The ExcelsiorLOAD
Trail” which compared P2Y12 inhibitors
pharmacodynamics in peri interventional setting,
reported that though prasugrel is more effective, the
prasugrel arm of the study had a higher incidence of
bleeding events.19 Earlier in 2013, European Society
of Cardiology recommended that prasugrel should
only be used in high-risk patients who require
elective stenting.20 Use of prasugrel in elective PCI
patients is still under debate and would need further
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studies to establish guidelines.
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The prasugrel package insert’s black box warning
recommends against its use in patient population
with a history of cerebrovascular events, in patients
aged 75 or older, and in patients weighing 60 kg
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using prasugrel for patients who undergo elective
PCIs. Prasugrel may have its benefits but judicious
approach by the physician is warranted to avoid
bleeding events. Secondly, it is also needful to
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CONCLUSIONS
According to our results, despite many years of
FDA approval and well-known contraindications,
prasugrel use in patients with known
contraindications is not uncommon.
AUTHOR AFFILIATIONS
1. Marshall University Joan C. Edwards School of
Medicine, Huntington, West Virginia
2. School of Medicine, MUST - Misr University for
Science & Technology, Cairo, Egypt
3. School of Medicine, Al-Najah University, Nablus,
Palestine

MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 5 Issue 3

38). J Am Coll Cardiol. 2014;63(3):225-32.
8. Nijjer SS, Davies JE, Francis DP. Quantitative
comparison of clopidogrel 600 mg, prasugrel and
ticagrelor, against clopidogrel 300 mg on major
adverse cardiovascular events and bleeding
in coronary stenting: synthesis of CURRENTOASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol.
2012;158(2):181-185.
9. De Servi S et al. Prasugrel and ticagrelor
compared to clopidogrel in non-ST-segment
elevation acute coronary syndromes undergoing
percutaneous coronary interventions: Certainties
and uncertainties. Int J Cardiol. 2015;181:443-445.
10. Greenhalgh J et al. Prasugrel (Efient(R)) with
percutaneous coronary intervention for treating
acute coronary syndromes (review of TA182):
systematic review and economic analysis. Health
Technol Assess. 2015;19(29):1-130.
11. Wiviott SD et al. Prasugrel versus clopidogrel in
patients with acute coronary syndromes. N Engl J
Med. 2007;357(20):2001-2015.
12. Alexopoulos D et al. Implementation of
contemporary oral antiplatelet treatment
guidelines in patients with acute coronary
syndrome undergoing percutaneous coronary
intervention: a report from the GReek AntiPlatelet
rEgistry (GRAPE). Int J Cardiol. 2013;168(6):53295335.
13. Sandhu A et al. Contemporary use of prasugrel in
clinical practice: insights from the Blue Cross Blue
Shield of Michigan Cardiovascular Consortium.
Circ Cardiovasc Qual Outcomes 2013;6(3):293298.
14. Hira RS et al. Frequency and practice-level
variation in inappropriate and nonrecommended
prasugrel prescribing: insights from the NCDR
PINNACLE registry. J Am Coll Cardiol. 2014;63(25
Pt A): 2876-2877.
15. Wallentin L et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J
Med. 2009;361(11):1045-1057.
16. Marchini J et al. An algorithm for use of prasugrel
(effient) in patients undergoing cardiac
catheterization and percutaneous coronary
intervention. Crit Pathw Cardiol. 2010;9(4):192198.
17. Trenk D et al. A randomized trial of prasugrel
versus clopidogrel in patients with high
platelet reactivity on clopidogrel after elective
percutaneous coronary intervention with
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

implantation of drug-eluting stents: results of
the TRIGGER-PCI (Testing Platelet Reactivity In
Patients Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy With
Prasugrel) study. J Am Coll Cardiol 2012;59(24):
2159-2164.
18. Damman P et al. Treatment patterns and
outcomes in patients undergoing percutaneous
coronary intervention treated with prasugrel
or clopidogrel (from the Swedish Coronary
Angiography and Angioplasty Registry [SCAAR]).
Am J Cardiol. 2014;113(1):64-69.
19. Hochholzer W et al. Randomized comparison
of different thienopyridine loading strategies
in patients undergoing elective coronary
intervention: The ExcelsiorLOAD Trial. JACC
Cardiovasc Interv. 2016;9(3): 219-227.
20. Task Force Members et al. 2013 ESC guidelines
on the management of stable coronary artery
disease: the task force on the management
of stable coronary artery disease of the
European Society of Cardiology. Eur Heart J.
2013;34(38):2949-3003.

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 5 Issue 3

